Alternative Splicing of CD55 Intron 7 Is Regulated by HnRNP L in Oral Squamous Cell Carcinoma.

doi:10.13701/j.cnki.kqyxyj.2016.10.002

Abstract

Abstract: Objective: To study the effect of splicing factor hnRNP L on alternative splicing of CD55 intron 7, a new target of hnRNP L in CAL 27 cells. Methods: An exon array data about hnRNP L down-regulation in cells in GEO database was re-analyzed with GEO2R online service. HnRNP L was knocked down by using siRNA in oral squamous cell carcinoma (OSCC) CAL 27 cells. Alternative splicing of CD55 intron 7 was analyzed by RT-PCR. Results: CD55 is a new target of hnRNP L. Knockdown of hnRNP L in CAL 27 cells significantly increased the inclusion of CD55 intron 7.Conclusion: The retention of CD55 intron 7 was regulated by hnRNP L. CD55 was the target of hnRNP L in OSCC cells.

Key words: HnRNP L, CD55, Alternative splicing, OSCC

CLC Number:

R739.8

ZHANG Si, LIU Miao-miao, LIU Pei-qi, JIA Rong, GUO Ji-hua.. Alternative Splicing of CD55 Intron 7 Is Regulated by HnRNP L in Oral Squamous Cell Carcinoma.[J]. Journal of Oral Science Research, 2016, 32(10): 1006-1009.

References

[1] Yuan W, Xie J, Long C, et al. Heterogeneous nuclear ribonucleoprotein L Is a subunit of human KMT3a/Set2 complex required for H3 Lys-36 trimethylation activity in vivo[J]. J Biol Chem,2009,284(23)∶15701-15707
[2] Guang S, Felthauser A M, Mertz J E. Binding of hnRNP L to the pre-mRNA processing enhancer of the herpes simplex virus thymidine kinase gene enhances both polyadenylation and nucleocytoplasmic export of intronless mRNAs[J]. Mol Cell Biol,2005,25(15)∶6303-6313
[3] Heiner M, Hui J, Schreiner S, et al. HnRNP L-mediated regulation of mammalian alternative splicing by interference with splice site recognition[J]. RNA Biol,2010,7(1);56-64
[4] Goehe R W, Shultz J C, Murudkar C, et al. hnRNP L regulates the tumorigenic capacity of lung cancer xenografts in mice via caspase-9 pre-mRNA processing[J]. J Clin Invest,2010,120(11)∶3923-3939
[5] Qi Y J, He Q Y, Ma Y F, et al. Proteomic identification of malignant transformation-related proteins in esophageal squamous cell carcinoma[J]. J Cell Biochem,2008,104(5)∶1625-1635
[6] Rossbach O, Hung L H, Khrameeva E, et al. Crosslinking-immunoprecipitation (iCLIP) analysis reveals global regulatory roles of hnRNP L[J]. RNA Biol,2014,11(2)∶146-155
[7] Pan Q, Shai O, Lee L J, et al. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing[J]. Nat Genet,2008,40(12)∶1413-1415
[8] Zhang J, Manley J L. Misregulation of pre-mRNA alternative splicing in cancer[J]. Cancer Discov,2013,3(11)∶1228-1237
[9] 刘佩琦,石黎明,贾荣. SRSF3调控口腔癌细胞中SPAG5外显子3的可变剪切的研究[J]. 口腔医学研究,2016,32(1)∶8-11
[10] Karni R, de Stanchina E, Lowe S W, et al. The gene encoding the splicing factor SF2/ASF is a proto-oncogene[J]. Nat Struct Mol Biol,2007,14(3)∶185-193
[11] Jia R, Li C, Mccoy J P, et al. SRp20 is a proto-oncogene critical for cell proliferation and tumor induction and maintenance[J]. Int J Biol Sci,2010,6(7)∶806-826
[12] Cohen-Eliav M, Golan-Gerstl R, Siegfried Z, et al. The splicing factor SRSF6 is amplified and is an oncoprotein in lung and colon cancers[J]. J Pathol,2013,229(4)∶630-639
[13] Hoffmann E M. Inhibition of complement by a substance isolated from human erythrocytes. II. Studies on the site and mechanism of action[J]. Immunochemistry,1969,6(3)∶405-419
[14] Mikesch J H, Buerger H, Simon R, et al. Decay-accelerating factor (CD55): a versatile acting molecule in human malignancies[J]. Biochim Biophys Acta,2006,1766(1)∶42-52